- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S4940
| Related Targets | PI3K Akt mTOR GSK-3 ATM/ATR DNA-PK AMPK PDPK1 PTEN PP2A |
|---|---|
| Other Antioxidant Products | (+)-Catechin Hydroxygenkwanin Silymarin (-)Epicatechin Syringic acid Cocoa Extract Oleuropein Clematis apiifolia Extract Parsley Extract Sesamol |
|
In vitro |
DMSO
: 25 mg/mL
(198.23 mM)
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 126.11 | Formula | C6H6O3 |
Storage (From the date of receipt) | 3 years -20°C powder (seal) |
|---|---|---|---|---|---|
| CAS No. | 118-71-8 | -- | Storage of Stock Solutions |
|
|
| Synonyms | Larixinic acid, Palatone, Veltol | Smiles | CC1=C(C(=O)C=CO1)O | ||
| In vitro |
Maltol can effectively protect nerve cells against oxidative damage caused by ROS in order to maintain normal physiological functions of cells and inhibit diabetes-induced oxidative stress and irreversible kidney damage. |
|---|---|
| In vivo |
For hepatoprotective activity in vivo, pretreatment with maltol (12.5, 25 and 50 mg/kg; 15 days) drastically prevents the elevated activities of aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) and triglyceride (TG) in serum and the levels of malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) in liver tissue. Meanwhile, the levels of hepatic antioxidant, such as catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) are elevated by maltol pretreatment, compared to the alcohol group. Maltol pretreatment significantly inhibits alcohol-induced hepatocyte apoptosis and fatty degeneration. It is effective in the prevention of alcohol-induced hepatic damage in mice. Also, maltol is suggested to be a functional agent to prevent the oxidative damage in the brain of mice. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05177484 | Recruiting | Cancer Colon |
The Royal Wolverhampton Hospitals NHS Trust|Norgine |
May 30 2022 | Phase 3 |
| NCT05126901 | Recruiting | Anemia|Iron-deficiency |
Shield Therapeutics |
October 4 2021 | Phase 3 |
| NCT04626414 | Unknown status | Anemia Iron Deficiency |
Shield Therapeutics |
September 28 2020 | Phase 1 |
| NCT03774615 | Terminated | Heart Failure Left Sided|Anemia Iron Deficiency |
Hannover Medical School|Shields Shields and Associates |
March 18 2019 | Phase 4 |
| NCT03181451 | Completed | Iron Deficiency Anaemia in Children|Iron-Deficiency |
Shield Therapeutics|Medpace Inc. |
March 14 2017 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.